{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T10:42:45Z","timestamp":1789123365993,"version":"build-2803163510"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,6,25]],"date-time":"2024-06-25T00:00:00Z","timestamp":1719273600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,6,25]],"date-time":"2024-06-25T00:00:00Z","timestamp":1719273600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>There is a paucity of comprehensive knowledge pertaining to the underlying mechanisms leading to gefitinib resistance in individuals diagnosed NSCLC harboring EGFR-sensitive mutations who inevitably develop resistance to gefitinib treatment within six months to one year. In our preceding investigations, we have noted a marked upregulation of IGFBP2 in the neoplastic tissues of NSCLC, predominantly in the periphery of the tissue, implying its plausible significance in NSCLC. Consequently, in the current research, we delved into the matter and ascertained the molecular mechanisms that underlie the participation of IGFBP2 in the emergence of gefitinib resistance in NSCLC cells. Firstly, the expression of IGFBP2 in the bronchoalveolar lavage fluid and lung cancer tissues of 20 NSCLC patients with gefitinib tolerance was found to be significantly higher than that of non-tolerant patients. Furthermore, in vitro and in vivo experiments demonstrated that IGFBP2 plays a significant role in the acquisition of gefitinib resistance. Mechanistically, IGFBP2 can activate STAT3 to enhance the transcriptional activity of CXCL1, thereby increasing the intracellular expression level of CXCL1, which contributes to the survival of lung cancer cells in the gefitinib environment. Additionally, we identified ITGA5 as a key player in IGFBP2-mediated gefitinib resistance, but it does not function as a membrane receptor in the process of linking IGFBP2 to intracellular signaling transduction. In conclusion, this study demonstrates the promoting role and mechanism of IGFBP2 in acquired gefitinib resistance caused by non-EGFR secondary mutations, suggesting the potential of IGFBP2 as a biomarker for gefitinib resistance and a potential intervention target.<\/jats:p>","DOI":"10.1038\/s41419-024-06843-y","type":"journal-article","created":{"date-parts":[[2024,6,25]],"date-time":"2024-06-25T16:02:37Z","timestamp":1719331357000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["IGFBP2\/ITGA5 promotes gefitinib resistance via activating STAT3\/CXCL1 axis in non-small cell lung cancer"],"prefix":"10.1038","volume":"15","author":[{"given":"Hengxiao","family":"Lu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiangshan","family":"Ai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingying","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolong","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liming","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiebo","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1554-2051","authenticated-orcid":false,"given":"Heng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6023-8203","authenticated-orcid":false,"given":"Shaoqiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,25]]},"reference":[{"key":"6843_CR1","first-page":"30","volume":"3","author":"M Mendez","year":"2011","unstructured":"Mendez M, Custodio A, Provencio M. New molecular targeted therapies for advanced non-small-cell lung cancer. J Thorac Dis. 2011;3:30\u201356.","journal-title":"J Thorac Dis"},{"key":"6843_CR2","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21708","volume":"72","author":"RL Siegel","year":"2022","unstructured":"Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72:7\u201333.","journal-title":"CA Cancer J Clin"},{"key":"6843_CR3","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.pharmthera.2019.06.005","volume":"202","author":"M Terlizzi","year":"2019","unstructured":"Terlizzi M, Colarusso C, Pinto A, Sorrentino R. Drug resistance in non-small cell lung cancer (NSCLC): Impact of genetic and non-genetic alterations on therapeutic regimen and responsiveness. Pharmacol Ther. 2019;202:140\u20138.","journal-title":"Pharmacol Ther"},{"key":"6843_CR4","doi-asserted-by":"publisher","first-page":"119","DOI":"10.4103\/0976-9668.184695","volume":"7","author":"F Nurwidya","year":"2016","unstructured":"Nurwidya F, Takahashi F, Takahashi K. Gefitinib in the treatment of nonsmall cell lung cancer with activating epidermal growth factor receptor mutation. J Nat Sci Biol Med. 2016;7:119\u201323.","journal-title":"J Nat Sci Biol Med"},{"key":"6843_CR5","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1038\/s41571-018-0081-4","volume":"15","author":"G Recondo","year":"2018","unstructured":"Recondo G, Facchinetti F, Olaussen KA, Besse B, Friboulet L. Making the first move in EGFR-driven or ALK-driven NSCLC: first-generation or next-generation TKI? Nat Rev Clin Oncol. 2018;15:694\u2013708.","journal-title":"Nat Rev Clin Oncol"},{"key":"6843_CR6","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.lungcan.2009.05.022","volume":"68","author":"T Onitsuka","year":"2010","unstructured":"Onitsuka T, Uramoto H, Nose N, Takenoyama M, Hanagiri T, Sugio K, et al. Acquired resistance to gefitinib: the contribution of mechanisms other than the T790M, MET, and HGF status. Lung Cancer. 2010;68:198\u2013203.","journal-title":"Lung Cancer"},{"key":"6843_CR7","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1038\/s41571-022-00680-8","volume":"19","author":"AJ Cooper","year":"2022","unstructured":"Cooper AJ, Sequist LV, Lin JJ. Author Correction: Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management. Nat Rev Clin Oncol. 2022;19:744.","journal-title":"Nat Rev Clin Oncol"},{"key":"6843_CR8","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.cca.2017.01.017","volume":"466","author":"Q Hu","year":"2017","unstructured":"Hu Q, Zhou Y, Ying K, Ruan W. IGFBP, a novel target of lung cancer? Clin Chim Acta. 2017;466:172\u20137.","journal-title":"Clin Chim Acta"},{"key":"6843_CR9","doi-asserted-by":"publisher","first-page":"427","DOI":"10.3892\/or.2020.7892","volume":"45","author":"LF Wei","year":"2021","unstructured":"Wei LF, Weng XF, Huang XC, Peng YH, Guo HP, Xu YW. IGFBP2 in cancer: pathological role and clinical significance (Review). Oncol Rep. 2021;45:427\u201338.","journal-title":"Oncol Rep"},{"key":"6843_CR10","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1210\/er.2001-0033","volume":"23","author":"SM Firth","year":"2002","unstructured":"Firth SM, Baxter RC. Cellular actions of the insulin-like growth factor binding proteins. Endocr Rev. 2002;23:824\u201354.","journal-title":"Endocr Rev"},{"key":"6843_CR11","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.canlet.2020.12.008","volume":"500","author":"L Sun","year":"2021","unstructured":"Sun L, Zhang X, Song Q, Liu L, Forbes E, Tian W, et al. IGFBP2 promotes tumor progression by inducing alternative polarization of macrophages in pancreatic ductal adenocarcinoma through the STAT3 pathway. Cancer Lett. 2021;500:132\u201346.","journal-title":"Cancer Lett"},{"key":"6843_CR12","doi-asserted-by":"publisher","first-page":"e74973","DOI":"10.1371\/journal.pone.0074973","volume":"8","author":"C Guo","year":"2013","unstructured":"Guo C, Lu H, Gao W, Wang L, Lu K, Wu S, et al. Insulin-like growth factor binding protein-2 level is increased in blood of lung cancer patients and associated with poor survival. PLoS ONE. 2013;8:e74973.","journal-title":"PLoS ONE"},{"key":"6843_CR13","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1007\/s10585-014-9647-4","volume":"31","author":"Q Hu","year":"2014","unstructured":"Hu Q, Huang L, Kuang X, Zhang H, Ling G, Chen X, et al. Is insulin-like growth factor binding protein 2 associated with metastasis in lung cancer? Clin Exp Metastasis. 2014;31:535\u201341.","journal-title":"Clin Exp Metastasis"},{"key":"6843_CR14","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.2353\/ajpath.2010.090500","volume":"176","author":"T Migita","year":"2010","unstructured":"Migita T, Narita T, Asaka R, Miyagi E, Nagano H, Nomura K, et al. Role of insulin-like growth factor binding protein 2 in lung adenocarcinoma: IGF-independent antiapoptotic effect via caspase-3. Am J Pathol. 2010;176:1756\u201366.","journal-title":"Am J Pathol"},{"key":"6843_CR15","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1080\/15384047.2019.1665952","volume":"21","author":"F Wang","year":"2020","unstructured":"Wang F, Zhang L, Sai B, Wang L, Zhang X, Zheng L, et al. BMSC-derived leptin and IGFBP2 promote erlotinib resistance in lung adenocarcinoma cells through IGF-1R activation in hypoxic environment. Cancer Biol Ther. 2020;21:61\u201371.","journal-title":"Cancer Biol Ther"},{"key":"6843_CR16","doi-asserted-by":"publisher","first-page":"205","DOI":"10.3390\/ijms24010205","volume":"24","author":"J Korbecki","year":"2022","unstructured":"Korbecki J, Maruszewska A, Bosiacki M, Chlubek D, Baranowska-Bosiacka I. The potential importance of CXCL1 in the physiological state and in noncancer diseases of the cardiovascular system, respiratory system and skin. Int J Mol Sci. 2022;24:205.","journal-title":"Int J Mol Sci"},{"key":"6843_CR17","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1038\/nrc1388","volume":"4","author":"F Balkwill","year":"2004","unstructured":"Balkwill F. Cancer and the chemokine network. Nat Rev Cancer. 2004;4:540\u201350.","journal-title":"Nat Rev Cancer"},{"key":"6843_CR18","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.cell.2012.04.042","volume":"150","author":"S Acharyya","year":"2012","unstructured":"Acharyya S, Oskarsson T, Vanharanta S, Malladi S, Kim J, Morris PG, et al. A CXCL1 paracrine network links cancer chemoresistance and metastasis. Cell. 2012;150:165\u201378.","journal-title":"Cell"},{"key":"6843_CR19","doi-asserted-by":"publisher","first-page":"S164","DOI":"10.21037\/jtd.2017.03.61","volume":"9","author":"A Spaks","year":"2017","unstructured":"Spaks A. Role of CXC group chemokines in lung cancer development and progression. J Thorac Dis. 2017;9:S164\u2013S71.","journal-title":"J Thorac Dis"},{"key":"6843_CR20","first-page":"2249","volume":"248","author":"TJ Peng","year":"2023","unstructured":"Peng TJ, Wu YC, Tang SJ, Sun GH, Sun KH. TGFbeta1 induces CXCL1 to promote stemness features in lung cancer. Exp Biol Med. 2023;248:2249\u201361.","journal-title":"Exp Biol Med"},{"key":"6843_CR21","doi-asserted-by":"publisher","first-page":"2767","DOI":"10.3892\/mmr.2014.3058","volume":"11","author":"BX Zhao","year":"2015","unstructured":"Zhao BX, Wang J, Song B, Wei H, Lv WP, Tian LM, et al. Establishment and biological characteristics of acquired gefitinib resistance in cell line NCI-H1975\/gefinitib-resistant with epidermal growth factor receptor T790M mutation. Mol Med Rep. 2015;11:2767\u201374.","journal-title":"Mol Med Rep"},{"key":"6843_CR22","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-017-3419-x","volume":"17","author":"SH Tu","year":"2017","unstructured":"Tu SH, Hsieh YC, Huang LC, Lin CY, Hsu KW, Hsieh WS, et al. A rapid and quantitative method to detect human circulating tumor cells in a preclinical animal model. BMC Cancer. 2017;17:440.","journal-title":"BMC Cancer"},{"key":"6843_CR23","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1158\/0008-5472.CAN-12-2095","volume":"73","author":"CH Liang","year":"2013","unstructured":"Liang CH, Chiu SY, Hsu IL, Wu YY, Tsai YT, Ke JY, et al. alpha-Catulin drives metastasis by activating ILK and driving an alphavbeta3 integrin signaling axis. Cancer Res. 2013;73:428\u201338.","journal-title":"Cancer Res"},{"key":"6843_CR24","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1038\/onc.2015.131","volume":"35","author":"CY Chua","year":"2016","unstructured":"Chua CY, Liu Y, Granberg KJ, Hu L, Haapasalo H, Annala MJ, et al. IGFBP2 potentiates nuclear EGFR-STAT3 signaling. Oncogene. 2016;35:738\u201347.","journal-title":"Oncogene"},{"key":"6843_CR25","first-page":"10","volume":"3","author":"C Ma","year":"2011","unstructured":"Ma C, Wei S, Song Y. T790M and acquired resistance of EGFR TKI: a literature review of clinical reports. J Thorac Dis. 2011;3:10\u20138.","journal-title":"J Thorac Dis"},{"key":"6843_CR26","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/j.apsb.2015.07.001","volume":"5","author":"L Huang","year":"2015","unstructured":"Huang L, Fu L. Mechanisms of resistance to EGFR tyrosine kinase inhibitors. Acta Pharm Sin B. 2015;5:390\u2013401.","journal-title":"Acta Pharm Sin B"},{"key":"6843_CR27","first-page":"4315","volume":"63","author":"H Wang","year":"2003","unstructured":"Wang H, Wang H, Shen W, Huang H, Hu L, Ramdas L, et al. Insulin-like growth factor binding protein 2 enhances glioblastoma invasion by activating invasion-enhancing genes. Cancer Res. 2003;63:4315\u201321.","journal-title":"Cancer Res"},{"key":"6843_CR28","doi-asserted-by":"publisher","first-page":"189","DOI":"10.4161\/cbt.5.2.2333","volume":"5","author":"S Chakrabarty","year":"2006","unstructured":"Chakrabarty S, Kondratick L. Insulin-like growth factor binding protein-2 stimulates proliferation and activates multiple cascades of the mitogen-activated protein kinase pathways in NIH-OVCAR3 human epithelial ovarian cancer cells. Cancer Biol Ther. 2006;5:189\u201397.","journal-title":"Cancer Biol Ther"},{"key":"6843_CR29","doi-asserted-by":"publisher","first-page":"14085","DOI":"10.1074\/jbc.M513686200","volume":"281","author":"GK Wang","year":"2006","unstructured":"Wang GK, Hu L, Fuller GN, Zhang W. An interaction between insulin-like growth factor-binding protein 2 (IGFBP2) and integrin alpha5 is essential for IGFBP2-induced cell mobility. J Biol Chem. 2006;281:14085\u201391.","journal-title":"J Biol Chem"},{"key":"6843_CR30","doi-asserted-by":"publisher","first-page":"11736","DOI":"10.1073\/pnas.0703145104","volume":"104","author":"SM Dunlap","year":"2007","unstructured":"Dunlap SM, Celestino J, Wang H, Jiang R, Holland EC, Fuller GN, et al. Insulin-like growth factor binding protein 2 promotes glioma development and progression. Proc Natl Acad Sci USA. 2007;104:11736\u201341.","journal-title":"Proc Natl Acad Sci USA"},{"key":"6843_CR31","doi-asserted-by":"publisher","first-page":"18634","DOI":"10.1074\/jbc.M609567200","volume":"282","author":"T Fukushima","year":"2007","unstructured":"Fukushima T, Tezuka T, Shimomura T, Nakano S, Kataoka H. Silencing of insulin-like growth factor-binding protein-2 in human glioblastoma cells reduces both invasiveness and expression of progression-associated gene CD24. J Biol Chem. 2007;282:18634\u201344.","journal-title":"J Biol Chem"},{"key":"6843_CR32","doi-asserted-by":"publisher","first-page":"535","DOI":"10.3892\/ol.2015.3945","volume":"11","author":"QF Deng","year":"2016","unstructured":"Deng QF, Su BO, Zhao YM, Tang L, Zhang J, Zhou CC. Integrin beta1-mediated acquired gefitinib resistance in non-small cell lung cancer cells occurs via the phosphoinositide 3-kinase-dependent pathway. Oncol Lett. 2016;11:535\u201342.","journal-title":"Oncol Lett"},{"key":"6843_CR33","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.3390\/cells11132078","volume":"11","author":"Q Sun","year":"2022","unstructured":"Sun Q, Lu Z, Zhang Y, Xue D, Xia H, She J, et al. Integrin beta3 promotes resistance to EGFR-TKI in non-small-cell lung cancer by upregulating AXL through the YAP pathway. Cells. 2022;11:2078.","journal-title":"Cells"},{"key":"6843_CR34","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.canlet.2020.02.036","volume":"477","author":"T Li","year":"2020","unstructured":"Li T, Zhang C, Zhao G, Zhang X, Hao M, Hassan S, et al. IGFBP2 regulates PD-L1 expression by activating the EGFR-STAT3 signaling pathway in malignant melanoma. Cancer Lett. 2020;477:19\u201330.","journal-title":"Cancer Lett"},{"key":"6843_CR35","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1124\/pr.56.4.3","volume":"56","author":"A Hoeben","year":"2004","unstructured":"Hoeben A, Landuyt B, Highley MS, Wildiers H, Van Oosterom AT, De Bruijn EA. Vascular endothelial growth factor and angiogenesis. Pharmacol Rev. 2004;56:549\u201380.","journal-title":"Pharmacol Rev"},{"key":"6843_CR36","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1046\/j.1432-1327.1999.00166.x","volume":"260","author":"A Wuyts","year":"1999","unstructured":"Wuyts A, Govaerts C, Struyf S, Lenaerts JP, Put W, Conings R, et al. Isolation of the CXC chemokines ENA-78, GRO alpha and GRO gamma from tumor cells and leukocytes reveals NH2-terminal heterogeneity. Functional comparison of different natural isoforms. Eur J Biochem. 1999;260:421\u20139.","journal-title":"Eur J Biochem"},{"key":"6843_CR37","doi-asserted-by":"publisher","first-page":"5346","DOI":"10.1158\/0008-5472.CAN-05-3684","volume":"66","author":"S Ueda","year":"2006","unstructured":"Ueda S, Basaki Y, Yoshie M, Ogawa K, Sakisaka S, Kuwano M, et al. PTEN\/Akt signaling through epidermal growth factor receptor is prerequisite for angiogenesis by hepatocellular carcinoma cells that is susceptible to inhibition by gefitinib. Cancer Res. 2006;66:5346\u201353.","journal-title":"Cancer Res"},{"key":"6843_CR38","doi-asserted-by":"publisher","DOI":"10.1177\/11769343211023767","volume":"17","author":"K Mao","year":"2021","unstructured":"Mao K, Lin F, Zhang Y, Zhou H. Identification of key genes and pathways in gefitinib-resistant lung adenocarcinoma using bioinformatics analysis. Evol Bioinform Online. 2021;17:11769343211023767.","journal-title":"Evol Bioinform Online"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-024-06843-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-024-06843-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-024-06843-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,25]],"date-time":"2024-06-25T16:02:44Z","timestamp":1719331364000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-024-06843-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,25]]},"references-count":38,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,6]]}},"alternative-id":["6843"],"URL":"https:\/\/doi.org\/10.1038\/s41419-024-06843-y","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,25]]},"assertion":[{"value":"7 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study has been approved by the Ethics Committee of the Xiangya Hospital of Central South University and Medical Research Ethics Committee of Affiliated Hospital of Jining Medical College. The animal protocols were approved by Xiangya Hospital of Central South University. (No. 202103714).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The informed consent was obtained from study participants.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"447"}}